Here's Why You Should Retain IRTC Stock in Your Portfolio for Now

iRhythm Holdings IRTC is well-positioned for solid growth over the next few quarters, courtesy of its strong volume-led momentum across channels, expanding footprint in primary care and deep integration with EHR systems. The company’s investments in AI, large-scale ECG data and clinical validation strengthen its competitive moat, while its push into predictive healthcare opens new long-term opportunities. However, reimbursement and regulatory pressures across key markets, reliance on successful channel expansion and intensifying competition from evolving monitoring technologies may pose challenges to sustained growth.

Shares of this Zacks Rank #3 (Hold) company have gained 9% so far this year against the industry’s 28.8% decline. However, the S&P 500 Index has increased 15.2% in the same timeframe.

iRhythm, a leader in ambulatory cardiac monitoring (ACM) operating a device-enabled digital diagnostics platform that integrates wearable biosensors (Zio), FDA-cleared AI algorithms and enterprise clinical workflows delivered through EHR systems, has a market capitalization of $3.69 billion.

The company’s earnings surpassed estimates in three of the trailing four quarters and missed one, delivering an average surprise of 366.5%.

Image Source: Zacks Investment Research

Positive Factors Driving IRTC Stock

Strong Volume-Led Growth Across Channels: iRhythm exited 2025 with exceptional momentum, driven by robust volume growth across its core business lines. The company delivered 27% year-over-year revenue growth in the fourth quarter of 2025, marking its fifth consecutive quarter of more than 20% growth. This performance underscores the durability of its platform and the breadth of its demand drivers across cardiology, primary care, innovative channels and international markets. Newer accounts contributed to expansion, with onboard customers accounting for a large portion of incremental volume. Management emphasized that sustained demand for its ambulatory cardiac monitoring services, combined with favorable pricing dynamics in 2025, supported strong top-line performance.

IRTC expects this momentum to continue, guiding for full-year 2026 revenues in the range of $870-$880 million, representing 16%-18% year-over-year growth, driven by sustained demand across the core business and a disciplined approach to forecasting newer and emerging channels. This consistent volume-led growth highlights IRTC’s ability to scale its business while continuing to penetrate underutilized segments of the market.

Expansion Into Primary Care & Workflow Integration: A strategic driver for iRhythm is its successful expansion beyond traditional cardiology settings into primary care, enabling earlier detection of arrhythmias and broadening its addressable market. The company now serves around 40,000 primary care physicians, with more than one-third of its total volume originating from these settings. This shift reflects a proactive care model aligned with value-based healthcare trends and population health management.

IRTC’s deep integration with electronic health record (EHR) systems has become a critical competitive advantage. More than half of its volume flows through EHR-integrated accounts and 75 of its top 100 customers are fully integrated. These integrations enhance workflow efficiency, improve prescribing consistency and create long-term customer stickiness. Management noted that integration drives a significant increase in utilization over time, reinforcing the scalability and durability of this model.

AI, Data and Clinical Evidence Create a Durable Competitive Moat: iRhythm has established a strong and competitive position by combining large-scale data, advanced AI and robust clinical validation. The company has amassed one of the world’s largest curated ECG datasets, over 3 billion hours of heartbeat recordings and more than 12 million patient reports, which power its FDA-cleared deep-learning algorithms and create a barrier for new entrants.

Findings from the CAMELOT and AVALON studies show that the Zio platform delivers superior diagnostic yield, faster detection and reduced healthcare utilization compared with alternative monitoring solutions. These benefits have been demonstrated across both Medicare and commercially insured populations, enhancing iRhythm’s credibility with payers and value-based care providers.

IRTC is expanding into predictive healthcare. Through its collaboration with Lucem Health, the company is leveraging AI to analyze medical records and identify patients at higher risk of arrhythmias before symptoms develop. Management sees this as an evolution from a device-focused service provider to a digital health intelligence platform capable of population-level risk assessment.

Supported by more than 135 peer-reviewed publications and continued innovation, including a third-generation AI algorithm under FDA review, iRhythm’s combination of data scale, technology and clinical validation creates a powerful, self-reinforcing moat that is difficult for competitors to match.

Headwinds That May Affect IRTC Stock

Reimbursement and Regulatory Pressures: Despite strong clinical validation, iRhythm continues to face reimbursement-related challenges in international markets. In Japan, Zio is currently reimbursed at rates comparable to traditional Holter monitors, which management considers inadequate and contingent on demonstrating superior clinical outcomes to support future pricing improvements. Similar issues persist in Europe, where reimbursement frameworks are highly fragmented and require extensive negotiations. In the United States, both Medicare and commercial insurers are focused on cost-effectiveness, which could hinder adoption if budget constraints tighten. The uneven pace of value-based care adoption introduces further uncertainty, as shifts in reimbursement policies may influence testing volumes and pricing.

Reliance on Continued Channel Expansion: The company’s growth strategy is closely tied to expanding its presence in primary care and developing new channel partnerships. While these initiatives show strong potential, they are still in the early phases and depend on significant changes in provider behavior across healthcare systems. Any shortfall in conversion rates, repeat monitoring or payer alignment could limit the anticipated growth trajectory.

Risk From Competition and Technological Advancements: Although iRhythm maintains a leading position in the LTCM market, it operates in a highly competitive landscape that includes traditional Holter monitoring, telemetry and emerging wearable technologies. Rapid innovation in this space increases the risk of competitors launching more cost-effective or consumer-oriented solutions, which could exert pressure on both market share and pricing.

iRhythm Holdings, Inc. Price

iRhythm Holdings, Inc. price | iRhythm Holdings, Inc. Quote

Estimate Trend

iRhythm is witnessing a positive estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for its loss has narrowed by 13 cents to 16 cents per share.

The Zacks Consensus Estimate for first-quarter 2026 revenues and loss per share is pegged at $193.8 million and 56 cents, respectively.

Stocks to Consider

Some better-ranked stocks from the broader medical space are Phibro Animal Health PAHC, GE HealthCare Technologies GEHC and Cardinal Health CAH.

Phibro Animal Health, currently sporting a Zacks Rank #1 (Strong Buy), reported second-quarter fiscal 2026 adjusted earnings per share (EPS) of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.

PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.4% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 20.1%.

GE HealthCare Technologies, currently carrying a Zacks Rank #2 (Buy), reported fourth-quarter 2025 adjusted EPS of $1.44, which surpassed the Zacks Consensus Estimate by 0.7%. Revenues of $5.7 billion beat the Zacks Consensus Estimate by 1.9%.

GEHC has an estimated long-term earnings growth rate of 9.1% compared with the industry’s 12.4% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 7.5%.

Cardinal Health, currently carrying a Zacks Rank #2, reported a second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.

CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.2% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 9.3%.

5 Stocks Set to Double

Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%.

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.

Today, See These 5 Potential Home Runs >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Cardinal Health, Inc. (CAH): Free Stock Analysis Report

Phibro Animal Health Corporation (PAHC): Free Stock Analysis Report

iRhythm Holdings, Inc. (IRTC): Free Stock Analysis Report

GE HealthCare Technologies Inc. (GEHC): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research